Literature DB >> 8575749

Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation.

T Kunieda1, C M Simonaro, M Yoshida, H Ikadai, G Levan, R J Desnick, E H Schuchman.   

Abstract

Mucopolysaccharidosis (MPS) type VI, the lysosomal storage disorder caused by the deficiency of arylsulfatase B (ARSB) activity, occurs in humans, cats, and rats. To characterize the molecular lesion(s) causing MPS VI in rats, cDNAs encoding rat ARSB were isolated from a rat liver cDNA library. The nucleotide and deduced amino acid sequences of rat ARSB had approximately 80 and 85% identity with the human ARSB sequences, respectively. The chromosomal location of the rat ARSB gene was determined by PCR analysis of rat-mouse somatic cell hybrid panel. The ARSB gene was assigned to rat chromosome 2, where the locus for the MPS VI phenotype in rats has been localized by linkage analysis. To identify the mutation(s) within the ARSB gene causing MPS VI in rats, the ARSB sequence were amplified from affected animals and completely sequenced. Notably, a homoallelic one-base insertion at nucleotide 507 (507insC) was identified, resulting in a frame shift mutation and premature termination at codon 258. The presence of the insertion completely correlated with the occurrence of the MPS VI phenotype among 66 members of the MPR rat colony. Thus, we conclude that 507insC is the causative mutation in these animals and that the MPS VI rats are an authentic model of human MPS VI.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575749     DOI: 10.1006/geno.1995.9962

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  14 in total

1.  Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.

Authors:  C Fillat; C M Simonaro; P L Yeyati; J L Abkowitz; M E Haskins; E H Schuchman
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

Review 2.  Chondroitin sulfate/dermatan sulfate sulfatases from mammals and bacteria.

Authors:  Shumin Wang; Kazuyuki Sugahara; Fuchuan Li
Journal:  Glycoconj J       Date:  2016-08-15       Impact factor: 2.916

3.  Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.

Authors:  Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

Review 4.  Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.

Authors:  Claude Szpirer
Journal:  J Biomed Sci       Date:  2020-08-02       Impact factor: 8.410

5.  Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.

Authors:  Calogera M Simonaro; Marina D'Angelo; Xingxuan He; Efrat Eliyahu; Nataly Shtraizent; Mark E Haskins; Edward H Schuchman
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

6.  ARSB gene variants causing Mucopolysaccharidosis VI in Miniature Pinscher and Miniature Schnauzer dogs.

Authors:  K Raj; L Berman-Booty; P Foureman; U Giger
Journal:  Anim Genet       Date:  2020-09-28       Impact factor: 3.169

Review 7.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

8.  Structural, compositional, and biomechanical alterations of the lumbar spine in rats with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).

Authors:  Alon Lai; Calogera M Simonaro; Edward H Schuchman; Yi Ge; Damien M Laudier; James C Iatridis
Journal:  J Orthop Res       Date:  2012-11-28       Impact factor: 3.494

9.  Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses.

Authors:  Edward H Schuchman; Yi Ge; Alon Lai; Yury Borisov; Meghan Faillace; Efrat Eliyahu; Xingxuan He; James Iatridis; Helen Vlassara; Gary Striker; Calogera M Simonaro
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

10.  Acid ceramidase maintains the chondrogenic phenotype of expanded primary chondrocytes and improves the chondrogenic differentiation of bone marrow-derived mesenchymal stem cells.

Authors:  Calogera M Simonaro; Sylvain Sachot; Yi Ge; Xingxuan He; Victor A Deangelis; Efrat Eliyahu; Daniel J Leong; Hui B Sun; Jeffrey B Mason; Mark E Haskins; Dean W Richardson; Edward H Schuchman
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.